Pain VAS 0‐100 (higher means worse) · carpal tunnel syndrome
1 finding from 1 review
CTS symptoms (Boston CTS questionnaire) ‐ long‐term improvement: > 3 monthsScale: 1 to 5, higher is worse · carpal tunnel syndrome
1 finding from 1 review
Function (Boston CTS questionnaire) ‐ Long‐term improvement: > 3 monthsScale: 1 to 5, higher is worse · carpal tunnel syndrome
1 finding from 1 review
Health‐related quality of life (EQ‐5D) ‐ Long‐term improvement: > 3 months Scale: 0 to 1, higher is better · carpal tunnel syndrome
1 finding from 1 review
HRQoL: EQ‐5D (0 to 1; a higher score indicates improved HRQoL) (final values) · Morton's neuroma
1 finding from 1 review
CTS symptoms (Boston CTS questionnaire) ‐ short‐term improvement: < 3 monthsScale: 1 to 5, higher is worse · carpal tunnel syndrome
1 finding from 1 review
CTS symptoms (Boston CTS questionnaire) ‐ long‐term improvement: > 3 monthsScale: 1 to 5, higher is worse · carpal tunnel syndrome
1 finding from 1 review
Function (Boston CTS questionnaire) ‐ Long‐term improvement: > 3 monthsScale: 1 to 5, higher is worse · carpal tunnel syndrome
1 finding from 1 review
Health‐related quality of life Assessed by: SeiQoL‐DW (higher scores mean better quality of life) · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
Participant‐reported improvement in sialorrhea in the short term · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
Cramp severity (0 to 10 VAS; higher = more pain) (after 6 weeks) · 50‐ to 60‐year‐old women with metabolic syndrome
1 finding from 1 review
Change in cramp severity (0 to 10 VAS; higher = worse pain) (after 6 weeks) · older adults with lower limb muscle cramps
1 finding from 1 review
Pain at 6 months or more; all doses Assessed by change from baseline, using a 0‐ to 100‐mm VAS, where higher scores indicate more pain) · people with diabetic peripheral neuropathy
1 finding from 1 review
Symptom quality and severity Assessed by NSS score (range of possible scores 0 to 9; higher scores indicate more symptoms) · the treatment of diabetic peripheral neuropathy
1 finding from 1 review
Change from baseline in 6MWT (metres) · children and adults with SMA type 3
1 finding from 1 review
Postoperative hand function (2 weeks postoperatively) Mean CTS‐FSS score (scale 1 to 5, where higher scores indicate worse function)
1 finding from 1 review
Reduction in fatigue · people with fatigue in Guillain‐Barré syndrome
Amantadine showed no clear difference in reduction in fatigue of at least 1‐point on the Fatigue Severity… compared with placebo (low certainty).
1 finding from 1 review
OR 0.56 [0.22, 1.35]
74 participants
Low
Short‐term (1 week) change in isolated movement, objective and subjective measures of speech production SARA. Scale from: 0 to 6. Higher scores indicate more severe speech disorder. · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (1 week) change in isolated movement, objective and subjective measures of speech production SARA. Scale from: 0 to 6. Higher scores indicate more severe speech disorder. · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review